Pasqal Holding
PSQL
7.26
+0.42
+6.14%
Pasqal Holding
US · PSQL
#3088 by market cap
Listed 2026
7.26
+0.42
+6.14%
Live - 5344 symbols - heartbeat 265s ago
· 2026-10-08 07:00
Pre-market
7.39
+1.79%
After-hours
7.36
+1.38%
Overnight
7.37
+1.52%
- Market cap
- 1.54B
- P/E (TTM)i
- -3.34
- P/Bi
- 10.66
- EPSi
- -2.17
- Div yieldi
- 0.00%
- 52W posi
- 7%
Reader sentiment
Are you bullish or bearish on PSQL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.05, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Latest year +429.91% YoY
Margins
- Gross margin
- 49.04%
- Operating margin
- -304.26%
- Net margin
- -560.81%
Key ratios & quality
- Enterprise valuei
- 1.59B
- Altman Z-Scorei
- 2.05
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 3.65M | 19.34M |
| Gross profit | 4.09M | 9.49M |
| Selling & admin expenses | 45.88M | 63.67M |
| Research & development | -- | -- |
| Operating profit | -47.65M | -58.86M |
| Pretax profit | -50.83M | -108.37M |
| Tax | -361.08K | 109.24K |
| Net profit | -50.46M | -108.48M |
| Basic EPS | 0 | -1 |
| Diluted EPS | -0.24 | -0.52 |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | -- |
| Research & development | -- | -- |
| Operating profit | -- | -- |
| Pretax profit | -- | -- |
| Tax | -- | -- |
| Net profit | -- | -- |
| Basic EPS | -- | -- |
| Diluted EPS | -- | -- |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 41.32M | 122.14M |
| Cash & ST investments | 2.52M | 83.32M |
| Inventory | 15.13M | 13.28M |
| Total assets | 131.12M | 220.62M |
| Total current liabilities | 50.55M | 180.97M |
| Short-term debt | 6.62M | 124.14M |
| Long-term debt | 8.17M | 8.97M |
| Total liabilities | 97,121,778.13 | 225,807,550.45 |
| Total equity | 34.00M | -5.19M |
| Retained earnings | -129.35M | -146.70M |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| Total current assets | 122.14M | 160.06M |
| Cash & ST investments | 83.32M | 126.56M |
| Inventory | 13.28M | 13.47M |
| Total assets | 220.62M | 268.16M |
| Total current liabilities | 180.97M | 71.99M |
| Short-term debt | 124.14M | 3.85M |
| Long-term debt | 8.97M | 8.90M |
| Total liabilities | 225,807,550.45 | 120,773,051.67 |
| Total equity | -5.19M | 147.38M |
| Retained earnings | -146.70M | -203.40M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -31.14M | -28.51M |
| Depreciation & amortization | 7.15M | 10.30M |
| Free cash flow | -52.01M | -41.22M |
| Dividends paid | 0 | 0 |
| Stock buybacks / issuance | 0 | 36.23M |
| Ending cash balance | 7.45M | 86.64M |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| Operating cash flow | -- | -- |
| Depreciation & amortization | -- | -- |
| Free cash flow | -- | -- |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | -- | -- |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -148.44 | -753.04 |
| ROA %i | -38.49 | -61.68 |
| ROIC %i | -81.27 | -105.86 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -1,311.60 | -533.60 |
| FCF / sales %i | -- | -- |
| Current ratioi | 0.82 | 0.67 |
| Quick ratioi | 0.42 | 0.58 |
| Debt / assetsi | 19.37 | 65.46 |
| LT debt / equityi | 55.22 | -- |
| Interest coveragei | -16.24 | -20.02 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-12 | 2026-06 |
|---|---|---|
| ROE %i | -753.04 | -92.01 |
| ROA %i | -61.68 | -50.57 |
| ROIC %i | -105.86 | -77.49 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -533.60 | -652.92 |
| FCF / sales %i | -- | -- |
| Current ratioi | 0.67 | 2.22 |
| Quick ratioi | 0.58 | 1.99 |
| Debt / assetsi | 65.46 | 8.74 |
| LT debt / equityi | -- | 13.29 |
| Interest coveragei | -20.02 | -24.48 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Quantum processing units (QPU) sales is the largest reported line at 45.28% of revenue, across 3 reported segments.
- Quantum processing units (QPU) -related services follows at 39.22%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Quantum processing units (QPU) sales45.28%
Quantum processing units (QPU) -related services39.22%
Cryostat sales15.50%
Region
France62.86%
Germany26.64%
Rest of Europe4.80%
Rest of the world2.22%
North America2.10%
Asia Pacific1.38%
Quote time 2026-10-08 07:00:10 · For reference only, not investment advice and not tailored to your situation.